Business Context and Reporting Period
This Form 6-K filing by EUDA Health Holdings Ltd covers the month of October 2025. The report details significant changes to the Company's Board of Directors, specifically the resignation of an independent director and the appointment of a successor.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance updates and contains no financial performance data.
Material Changes
- Resignation: Prof. Wong Kong Yew resigned as an independent director, Chairman of the Compensation Committee, and member of the Audit and Nomination Committees, effective October 23, 2025. The resignation was not due to any disagreement with the Company.
- Appointment: Huang Bo was appointed as an independent director, Chairman of the Compensation Committee, and member of the Audit and Nomination Committees, effective October 24, 2025.
Outlook, Risks, and Management Commentary
Management Commentary on New Director: The Board determined that Mr. Huang qualifies as an independent director under Nasdaq rules and SEC Rule 10A-3. Although Mr. Huang is the General Manager of Shenzhen Key Lock Biotechnology Co., Ltd. (a company owned by the same entity that owns a key business partner of EUDA), the Board concluded this relationship would not interfere with his independent judgment.
Risks and Contingencies: The filing states there are no related-party transactions involving Mr. Huang requiring disclosure and no arrangements regarding his selection that need to be disclosed.
Key Facts for Investor Verification
- Verify the independence status of the new director, Huang Bo, given his role at Shenzhen Key Lock Biotechnology Co., Ltd., which is linked to EUDA's key business partner for stem cell and immunotherapy distribution rights.
- Confirm the effective dates of the board changes: Resignation on October 23, 2025, and Appointment on October 24, 2025.
- Note that this filing contains no financial results; investors should refer to the most recent Form 20-F or quarterly reports for financial metrics.